

Webinar

Fair Pricing of Medicines: What Lessons From Growing Transparency in Vaccines Prices?

Suerie Moon, Tania Cernuschi

27 February 2020

Q&A Session with the Participants

16:16:04

From valerie Laigle : what do you mean by equally r and d cost

16:17:04

From valerie Laigle : r and cost related to the medicine or also failure r and d cost

16:22:57

From Janni Bækkelund Petersen to All panelists : How come the informations on costs are disclosed for sofosbuvir, but not for many other drugs?

16:27:17

From Global Health Centre Research, Graduate Institute Geneva : Please select the option send to all panelists and attendees so everyone can see the questions. Thank you.

16:27:51

From Krycia Cowling : I understand this is not a formula, but can you share a bit more about the idea for how shared costs (e.g. R&D) would be fairly split across buyers? This seems to be one of the more widely disagreed upon aspects.

16:28:22

From Sascha Moore Boffi : My apologies. This framework would require absolute transparency from pharma on R&D costs for it to be workable. Or are there alternatives?

16:29:17

From HAN YANG CHUNG : Can you explain at this stage, how we can use the framework for country MOH in discussion on fair pricing/price regulation?

16:30:27

From Aravind Menon to All panelists : Thank you for hosting the webinar on such a critical issue. I have to leave due to a conflicting meeting but I look forward to catching up on the rest from your recording.

16:35:58

From Sascha Moore Boffi : Could R&D transparency without price transparency avoid some of the potential impacts of price transparency?

16:36:34

From Danielle Mae Navarro : Please clarify whether the conceptual framework would be more applicable to countries who engage in national/regional medicine procurement mechanisms than for countries where private sector medicine distribution is more prevalent and medicines are out of pocket expenses for majority of the population?

16:38:18

From Reinhard Huss to All panelists : Can and should pricing transparency be made a legal requirement of all manufacturers and suppliers, if they want to supply national health systems (tax financed and social insurance financed)?

16:40:14

From Adriana Ivama Brummell : Congrats to both panelists! Great presentations! Tania, is there is any similar ongoing initiative for price information sharing for medicines that would be open or at least for government officials?

16:46:14

From Reinhard Huss to All panelists : Should (for the assessment of fairness) profits be separated into private profits (for investor) and social profits (reinvestment into development of manufacturers)? Should fair private profit rates be linked to interest rates paid for savings of citizens?

16:51:51

From Fabius Vieira Leineweber : Do you think that this fair pricing framework would address some market incentives by increasing the price of some medicines for neglected diseases?

16:52:34

From Derek Queisser de Stockalper : Have you considered so-called health outcome impact solutions, where price - and the drug itself - becomes only one building block of a more transversal solution to address a key local health need ? This could create novel price blending opportunities/ecosystems going forward...

16:52:35

From Roz Scourse : Thanks so much! Super interesting... Tania, you said that the evidence around the impacts of price transparency are inconclusive, but this shows concretely that price transparency has lowered prices (and other positive impacts). Have you seen any of the negative impacts predicted related to price transparency (as you showed in your previous slide e.g. raised prices, collusion etc.)?

16:54:52

From Luciano Filho to All panelists : Great presentation! just a quick one. So fair price in your framework would always mean affordability as the capacity to pay or affordability as a price that is genuinely low-cost for a country?

16:55:57

From Wilbert Bannenberg : https://www.who.int/medicines/access/fair_pricing/en/

16:56:05 From Sascha Moore Boffi : Cost of capital as a way of calculating failures might include a bias because of the high return on investment brought by the high prices of successful medicines?

16:58:58

From Thomas Kanga-Tona to All panelists : Ms Moon, we've developed a model for the calculation of fair prices ourselves - how do you take into account the added therapeutic value of the considered drug in your framework ?

17:00:50

From giustino adesso : In Venezuela there is an organic law on fair prices. When they have tried to apply to medicines, the lack of technical expertise of officials responsible for reviewing cost data from providers limits progress in practice

17:06:05

From Janni Bækkelund Petersen to All panelists : Have to go, but thank you very much for a super webinar!

17:06:34

From Wilbert Bannenberg to All panelists : thanks for two great presentations. Have to go... Wilbert

17:09:18

From Sascha Moore Boffi : Thank you very much to both presenters.

17:13:07

From Ada Maldonado to All panelists : Thank you from Peru

17:13:23

From Angela Acosta : thank you